Faeth Therapeutics, Inc.

US$22.05As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:FTHHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (37.83%)
Div yield —
ROE (229.61%)
Biotechnology
Beta (5Y) (0.18)
PE TTM —
TSR TTM 140.46%
Mkt cap US$569.8M
ROIC (55.76%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$22
0.32%
(72.07%)
Hold 3|0|4|1|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.24
0.24
0.24
0.27
26.42%
22.84%
18.26%
25.06%
Revenue$M
45.44
44.96
47.37
49.85
9.83%
6.47%
8.36%
12.62%
Peers (US$569.8M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.536
(0.238)
(0.152)
EBIT/Intx
0.850
0.664
0.672
Own earn%
19.82
(51.71)
(50.45)
Sh yield%
19.98
25.47
26.39
Owners
Insiders/Inst%
8.24
40.07
Short interest%
3.95
SBC / revenue%
0.25
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
15–21
$1 testx
−1.1
Incr. ROIC%
1